Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased